•   A phase II RCT (NCT02708095) demonstrated efficacy in alleviating arthritis in active SLE patients•   A phase IIb study (PF-06700841) will investigate a selective JAK1 inhibitor in moderate-to-severe active SLE patientswithout renal or cerebral involvement who show inadequate response to standard therapies•   A phase II clinical trial on solcitinib (a selective JAK1 inhibitor) (NCT01777256) was discontinued owing to severe drugreaction with eosinophilia and systemic symptoms (DRESS) syndrome and hepatic function abnormalities. The gene discussed is JAK1; the disease is arthritic joint disease.